Janus Henderson Group PLC's Form 4 filing
Oruka Therapeutics, Inc. (ORKA) · filed Jul 12, 2024
- Accession no.
- 0001437749-24-022708
- Filed
- Jul 12, 2024, 7:38 PM ET
- Trade date
- Jul 3-11, 2024
- Filing delay
- 9 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 9 non-derivative transactions and 0 derivative transactions. Open-market purchases total $1.43M. It was filed 9 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Janus Henderson Group PLCCIK 0001274173 | 10% Owner |
| Janus Henderson Biotech Innovation Master Fund LtdCIK 0002030299 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 3, 2024 | Common Stock | PPurchaseAcquired | +166,042 | $3.55 | +$589,565.33 | 1,648,577 | Indirect | |
| Jul 5, 2024 | Common Stock | PPurchaseAcquired | +23,326 | $3.43 | +$80,015.18 | 1,671,903 | Indirect | |
| Jul 5, 2024 | Common Stock | PPurchaseAcquired | +5,000 | $3.41 | +$17,050 | 1,676,903 | Indirect | |
| Jul 8, 2024 | Common Stock | PPurchaseAcquired | +29,892 | $3.41 | +$101,973.57 | 1,706,795 | Indirect | |
| Jul 8, 2024 | Common Stock | PPurchaseAcquired | +17,600 | $3.54 | +$62,216 | 1,724,395 | Indirect | |
| Jul 9, 2024 | Common Stock | PPurchaseAcquired | +16,917 | $3.43 | +$58,091.29 | 1,741,312 | Indirect | |
| Jul 10, 2024 | Common Stock | PPurchaseAcquired | +33,500 | $3.46 | +$116,067.45 | 1,774,812 | Indirect | |
| Jul 10, 2024 | Common Stock | PPurchaseAcquired | +21,963 | $3.46 | +$76,062.26 | 1,796,775 | Indirect | |
| Jul 11, 2024 | Common Stock | PPurchaseAcquired | +94,537 | $3.45 | +$326,303.91 | 1,891,312 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.